Financial Performance - For the six months ended September 30, 2024, the group recorded total revenue of approximately HKD 10,435,000, a decrease of about 60.05% compared to HKD 26,125,000 for the same period in 2023[4] - The profit attributable to owners of the company for the six months ended September 30, 2024, was approximately HKD 7,602,000, compared to a loss of HKD 7,160,000 in the same period of 2023[4] - The operating profit for the six months ended September 30, 2024, was HKD 7,749,000, compared to an operating loss of HKD 6,201,000 in the same period of 2023[5] - The company reported a total comprehensive income of HKD 7,265,000 for the period, compared to a total comprehensive loss of HKD 8,215,000 in the same period of 2023[8] - The group recorded a profit attributable to owners of approximately HKD 7,602,000, compared to a loss of HKD 7,161,000 in the previous year, mainly due to the recognition of a gain of approximately HKD 10,458,000 from the sale of a subsidiary[44] Earnings and Losses - The basic and diluted earnings per share for the period were HKD 1.349, compared to a loss per share of HKD 1.270 in the same period of 2023[8] - Basic loss per share for the six months ended September 30, 2024, was HKD 0.0135, compared to a loss of HKD 0.0127 in 2023, reflecting a slight increase in loss per share[29] - The company recorded a loss of HKD 7,161,000 for the period, with cumulative losses reaching HKD 713,666,000[12] Assets and Liabilities - The total assets as of September 30, 2024, amounted to HKD 24,668,000, a decrease from HKD 29,146,000 as of March 31, 2024[9] - The total liabilities as of September 30, 2024, were HKD 15,996,000, down from HKD 27,739,000 as of March 31, 2024[11] - The equity attributable to owners of the company increased to HKD 11,693,000 as of September 30, 2024, compared to HKD 4,357,000 as of March 31, 2024[9] - The total current assets as of September 30, 2024, were approximately HKD 6,560,000, compared to HKD 8,705,000 as of March 31, 2024[50] - The total current liabilities as of September 30, 2024, were approximately HKD 14,662,000, down from HKD 25,615,000 as of March 31, 2024[50] Cash Flow - The net cash generated from operating activities was HKD 476,000, down from HKD 909,000 in the previous year[15] - The company experienced a net cash decrease of HKD 2,652,000, compared to a decrease of HKD 13,038,000 in the same period last year[15] - The company's cash and cash equivalents at the end of the period were HKD 1,630,000, down from HKD 4,983,000 at the end of the previous year[15] - The total cash and cash equivalents as of September 30, 2024, were approximately HKD 1,630,000, down from HKD 3,644,000 as of March 31, 2024[50] Expenses - The total comprehensive expenses for the period amounted to HKD 8,215,000, compared to HKD 7,336,000 in the previous year[15] - Sales and distribution expenses for the review period were approximately HKD 1,549,000, down about 55.98% from HKD 3,519,000 in the previous year[44] - Administrative expenses were approximately HKD 9,459,000, representing a decrease of about 56.77% compared to HKD 21,881,000 last year, primarily due to reduced employee costs[44] Employee Information - The group employed 118 full-time employees as of September 30, 2024, down from 137 on March 31, 2024, with total employee costs amounting to approximately HKD 6,699,000 compared to HKD 11,214,000 in 2023[60] - Total employee benefits for key management personnel decreased to HKD 1,605,000 in 2024 from HKD 2,079,000 in 2023, reflecting a reduction in management compensation[40] Strategic Developments - The group is entering a transformation phase, shifting its strategic focus towards integrated digital healthcare and health management services[46] - The collaboration with Xiamen Yue'er Bay and Qingdao Yue'er Bay has been approved by relevant regulatory authorities, marking a significant step towards establishing a diversified and stable revenue base[47] Corporate Governance - The company has complied with the corporate governance code as per GEM listing rules during the review period[83] - The remuneration committee is responsible for determining the specific remuneration packages of all executive directors[84] - The nomination and corporate governance committee was established to review the board's structure and recommend suitable candidates for board membership[85] - The audit committee was established on November 2, 2001, consisting of three independent non-executive directors[87] - The audit committee's main responsibilities include ensuring adequate financial controls and monitoring risk management systems[87] Shareholder Information - As of September 30, 2024, Mr. Wu Zhi Long holds a beneficial interest in 11,800,000 shares, representing approximately 2.09% of the issued share capital[67] - The company has a total of 316,391,892 shares held by its beneficial owner, representing 56.13% of the issued shares[72] - Zheng Huixian holds 328,191,892 shares, accounting for 58.22% of the total issued shares[72] - New Hope International holds 68,643,507 shares, which is 12.18% of the total issued shares[72] Other Information - The company did not recommend the distribution of dividends for the six months ended September 30, 2024, consistent with the previous year[4] - The company has not applied any new accounting standards that have been issued but not yet effective, which would have a significant impact on its financial statements[20] - There were no significant events occurring after the reporting period[66] - The company has not purchased, sold, or redeemed any of its listed securities during the six months ending September 30, 2024[78] - There are no outstanding stock options under the stock option plan as of September 30, 2024[77]
金威医疗(08143) - 2025 - 中期财报